BNTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

823.11M

-30.83%

0.473

-56.23%

219.20M

+19.91%

-2.067

+19.51%

268.65M

+3.01%

-2.147

+34.22%

Estimates Revision

The market is revising Upward the revenue expectations for BioNTech SE (BNTX) for FY2025, with the revenue forecasts being adjusted by 13.19% over the past three months. During the same period, the stock price has changed by -4.03%.

Revenue Estimates for FY2025

Revise Upward

+13.19%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-16.51%

In Past 3 Month

Stock Price

Go Down

-4.03%

In Past 3 Month

16 Analyst Rating

Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 139.27 USD with a low forecast of 107.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

3 Hold

0 Sell

Strong Buy

Current: 93.940

Low

107.00

Averages

139.27

High

181.00

Current: 93.940

Low

107.00

Averages

139.27

High

181.00

Berenberg

Harry Gillis

Buy

maintain

$150 -> $155

2025-12-11

New

Reason

Berenberg

Harry Gillis

Price Target

$150 -> $155

2025-12-11

New

maintain

Buy

Reason

Berenberg analyst Harry Gillis raised the firm's price target on BioNTech to $155 from $150 and keeps a Buy rating on the shares.

H.C. Wainwright

Buy

maintain

$136 -> $140

2025-11-10

Reason

H.C. Wainwright

Price Target

$136 -> $140

2025-11-10

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on BioNTech to $140 from $136 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report to reflect lower operating expenses.

UBS

Eliana Merle

Neutral

maintain

$115 -> $117

2025-11-06

Reason

UBS

Eliana Merle

Price Target

$115 -> $117

2025-11-06

maintain

Neutral

Reason

UBS analyst Eliana Merle raised the firm's price target on BioNTech to $117 from $115 and keeps a Neutral rating on the shares. The Pumitamig data update in first-line treatment for small cell lung cancer has de-risked the pipeline, the analyst tells investors in a research note.

BofA

Tazeen Ahmad

Buy

maintain

$130 -> $134

2025-11-04

Reason

BofA

Tazeen Ahmad

Price Target

$130 -> $134

2025-11-04

maintain

Buy

Reason

BofA analyst Tazeen Ahmad raised the firm's price target on BioNTech to $134 from $130 and keeps a Buy rating on the shares. Despite the COVID revenue beat, the firm continues to see risk for long-term adoption. However, it notes that the company is well-positioned to advance the oncology franchise, which BofA sees as "the key long-term driver."

Clear Street

Bill Maughan

Buy

downgrade

$185 -> $181

2025-11-03

Reason

Clear Street

Bill Maughan

Price Target

$185 -> $181

2025-11-03

downgrade

Buy

Reason

Clear Street analyst Bill Maughan lowered the firm's price target on BioNTech (BNTX) to $181 from $185 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report. Today's selloff is related to the regulatory readthrough from an adverse FDA communication to uniQure (QURE), the analyst tells investors in a research note. Clear Street views BioNTech's updated guidance as a "healthy sign of a company improving its operating efficiency."

Morgan Stanley

Overweight

maintain

$131 -> $134

2025-11-03

Reason

Morgan Stanley

Price Target

$131 -> $134

2025-11-03

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on BioNTech to $134 from $131 and keeps an Overweight rating on the shares. Comirnaty Q3 revenues were ahead of consensus, and the company noted that the COVID-19 franchise is performing in-line with expectations, the analyst tells investors in a research note. The firm added BioNTech has seen and continues to expect stable share andd pricing.

Valuation Metrics

The current forward P/E ratio for Biontech SE (BNTX.O) is -17.17, compared to its 5-year average forward P/E of -5.10. For a more detailed relative valuation and DCF analysis to assess Biontech SE 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.10

Current PE

-17.17

Overvalued PE

4.93

Undervalued PE

-15.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

2.69

Current EV/EBITDA

-6.00

Overvalued EV/EBITDA

12.59

Undervalued EV/EBITDA

-7.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.96

Current PS

8.94

Overvalued PS

8.81

Undervalued PS

3.12

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BNTX News & Events

Events Timeline

No data

News

9.0

12-12Benzinga

FDA Considers Black Box Warning for COVID Vaccines Amid Expert Opposition

9.0

12-09Benzinga

BioNTech-Bristol Treatment Offers Promise for Breast Cancer Patients with Limited Alternatives

9.0

12-09Globenewswire

BioNTech and BMS Report 61.5% Efficacy for Pumitamig in TNBC Phase 2 Trial

People Also Watch

Frequently Asked Questions

What is Biontech SE (BNTX) stock price today?

The current price of BNTX is 93.94 USD — it has decreased -0.92 % in the last trading day.

What is Biontech SE (BNTX)'s business?

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

What is the price predicton of BNTX Stock?

What is Biontech SE (BNTX)'s revenue for the last quarter?

Biontech SE revenue for the last quarter amounts to 1.52B USD, increased 22.02 % YoY.

What is Biontech SE (BNTX)'s earnings per share (EPS) for the last quarter?

Biontech SE. EPS for the last quarter amounts to -0.12 USD, decreased -114.81 % YoY.

What changes have occurred in the market's expectations for Biontech SE (BNTX)'s fundamentals?

How many employees does Biontech SE (BNTX). have?

Biontech SE (BNTX) has 6772 emplpoyees as of December 15 2025.

What is Biontech SE (BNTX) market cap?

Today BNTX has the market capitalization of 22.80B USD.